Truist Securities Maintains Buy on WAVE Life Sciences, Lowers Price Target to $15

Benzinga Newsdesk www.benzinga.com Negative 47.4%

Neg 47.4% Neu 0% Pos 0%

Truist Securities analyst Danielle Brill maintains WAVE Life Sciences (NASDAQ:WVE) with a Buy and lowers the price target from $50 to $15.